Comparative study of different doses of platelet-rich plasma in the treatment of meniscus injury of grade I and II knee joint in young people

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057591

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee meniscus injury

Interventions

PRP low dose group:Autologous platelet-rich plasma 2mL

PRP middle dose group:Autologous platelet-rich plasma 5mL

PRP high dose group:Autologous platelet-rich plasma 8mL

Plasma placebo low dose group:Plasma placebo 2mL

Plasma placebo middle dose group:Plasma placebo 5mL

Plasma placebo high dose group:Plasma placebo 8mL

Eligibility

Sex/Gender

All

Age

18 Years to 44 Years

Inclusion criteria

Inclusion criteria: 1. According to the diagnostic criteria of BASK National Consensus 2018, and the meniscus injury I and II degree was diagnosed by MRI; 2. According to WHO age Classification Standard, young people aged 18-44 with full capacity for civil conduct should be selected; 3. Hb > 120g/L, PLT > 120*10^9/L; 4. The coagulation function and transmission of nine normal; 5. Subjects did not take glucosamine hydrochloride and other drugs to protect articular cartilage or received injection of sodium hyaluronate within 3 months before the test; 6. Subjects and their families are informed of the research content and voluntarily sign relevant agreements.

Exclusion criteria

Exclusion criteria: 1. Those who do not cooperate with the study; 2. Patients with serious articular cartilage injury and cruciate ligament injury without repair or reconstruction; 3. Injection site infection; 4. Sepsis; 5. Patients with dysfunction of important organs such as heart, liver and kidney; 6. Patients with complicated immunodeficiency or severe infection; 7. Non-steroidal anti-inflammatory and analgesic drugs were not stopped for more than 48 hours; 8. Hematopoietic system or skeletal system tumors; 9. Systemic corticosteroid treatment was not stopped for more than 2 weeks.

Design outcomes

Primary

Measure	Time frame
Lysholm scale;MRI;	—

Secondary

Measure	Time frame
Visual analogue scale, VAS;36-item Short Form Health Survey;Musculoskeletal ultrasound;Adverse reactions;	—

Countries

China

Contacts

Public ContactCheng Chao

The PLA Western Theater Command General Hospital

cc200514@163.com+86 18040314008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026